Abstract Library

#2723 Achieving Objective Response in Treatment of Non-Resectable Neuroendocrine Tumors Does Not Predict Longer Time to Progression Compared to Achieving Stable Disease

Introduction: There are several treatment modalities for unresectable neuroendocrine tumors. Traditionally the goal of these treatments are to reduce the tumor load; objective response (OR). Less emphasis has been put on inducing the tumors to stop growing without reduction in total tumor load; stable disease (SD).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Thiis-Evensen E

Authors: Thiis-Evensen E, Sponheim J,

Keywords: Neuroendocrine tumor, Treatment, Radiology, Time to progression,

#2137 Evaluation of Multidisciplinary Tumor Board Decisions in the Management of Neuroendocrine Tumors: Impact of Expert Centers

Introduction: ENETS requires Centers of Excellence to discuss all new gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients in a multidisciplinary tumor board (MDT) but the true value of the MDT has never been assessed

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Zandee W

Authors: Zandee W, Merola E, de Mestier L, Klümpen H, Geboes K,

Keywords: Standard of Care, Multidisciplinary Tumor Board, Quality of Care,

#2095 Progression of Mesenteric Metastasis in Small Intestinal Neuroendocrine Tumors

Introduction: A metastatic mesenteric mass is a hallmark of small intestinal neuroendocrine tumours (SI-NETs). However, little is known about the development of a SI-NET associated mesenteric mass over time.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Blazevic A

Authors: Blazevic A, Feelders R, Hofland J, Franssen G, Van Velthuysen M,

Keywords: Small intestinal neuroendocrine tumor, Mesenteric metastasis, Radiology, Peptide receptor radionuclide therapy,

#2053 Value of Tumor Growth Rate (TGR) as an Early Predictor of Patients’ Outcome in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs): The GREPONET Study

Introduction: TGR (% change in tumour volume per month (%/m)) is postulated to be an early radiological biomarker to overcome limitations of RECIST in NETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Lamarca A

Authors: Lamarca A, Crona J, Ronot M, Opalinska M, Lopez Lopez C,

Keywords: tumor growth rate, response, progression-free survival, follow-up, neuroendocrine tumor, prognosis, TGR, RECIST, radiology,

#1652 National Cancer Intelligence Network Data for NET in England- Accuracy by Comparison to a Large Clinical Database

Introduction: Data on all cancers is collected centrally for England using ICD-O-3 coding and it is entered into the National Cancer Intelligence Network (NCIN) database. Every pathology report is collected together with laboratory, radiology, admission episodes, clinic review, survival together with demographics.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Ramage J

Authors: Ramage J, Rous B, Sissons M, Talbot D, Reed N,

Keywords: registry, incidence, mortality,